Our top pick for
Building a portfolio
San Diego-based BioAtla, a company that produces cancer therapies, wrapped its initial public offering.
|52-week range||USD$27.15 - USD$76.63|
|50-day moving average||USD$56.0729|
|200-day moving average||USD$48.5243|
|Wall St. target price||USD$76.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$-19,504,000|
|Return on assets TTM||-14.8%|
|Return on equity TTM||-46.57%|
|Market capitalisation||USD$1.5 billion|
TTM: trailing 12 months
There are currently 2.1 million BioAtla shares held short by investors – that's known as BioAtla's "short interest". This figure is 54.1% up from 1.4 million last month.
There are a few different ways that this level of interest in shorting BioAtla shares can be evaluated.
BioAtla's "short interest ratio" (SIR) is the quantity of BioAtla shares currently shorted divided by the average quantity of BioAtla shares traded daily (recently around 395158.06451613). BioAtla's SIR currently stands at 5.27. In other words for every 100,000 BioAtla shares traded daily on the market, roughly 5270 shares are currently held short.
To gain some more context, you can compare BioAtla's short interest ratio against those of similar companies.
However BioAtla's short interest can also be evaluated against the total number of BioAtla shares, or, against the total number of tradable BioAtla shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioAtla's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 BioAtla shares in existence, roughly 60 shares are currently held short) or 0.0685% of the tradable shares (for every 100,000 tradable BioAtla shares, roughly 69 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against BioAtla.
Find out more about how you can short BioAtla stock.
We're not expecting BioAtla to pay a dividend over the next 12 months.
BioAtla, Inc. , a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California. .
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZIONL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.